CNS Disorders  >>  AZD2066  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
AZD2066 / AstraZeneca
NCT01145755: 6-week Study Treatment to Evaluate the Safety and Effectiveness of AZD2066 in Patients With Major Depressive Disorder

Terminated
2a
131
US
AZD2066, Placebo, Duloxetine
AstraZeneca
Major Depressive Disorder
11/10
11/10

Download Options